Baseline characteristics of patients with IBD with COVID-19
| Overall (n=79) | CD (n=32) | UC (n=47) | |
| Age, years, median (range) | 45 (18–80) | 39 (18–73) | 51 (23–80) |
| Female, n (%) | 35 (44.3%) | 15 (46%) | 20 (43%) |
| Active disease, n (%) | 22 (28%) | 4 (12%) | 18 (35%) |
| Concomitant therapy for IBD, n (%) | |||
| None | 5 (6%) | 5 (16%) | 0 (0%) |
| Aminosalicylates | 24 (30%) | 3 (9%) | 21 (45%) |
| Thiopurines | 6 (8%) | 1 (3%) | 5 (11%) |
| Systemic corticosteroids | 9 (11%) | 1 (3%) | 8 (17%) |
| Calcineurin inhibitors | 1 (1%) | 1 (3%) | 0 (0%) |
| Anti-TNF | 29 (37%) | 15 (47%) | 14 (30%) |
| Vedolizumab | 15 (20%) | 5 (16%) | 10 (21%) |
| Ustekinumab | 3 (4%) | 3 (9%) | 0 (0%) |
| Investigational drugs (within a clinical trial) | 2 (2%) | 2 (6%) | 1 (2%) |
| Pregnancy,n (%) | 1 (1%) | 0 (0%) | 1 (2%) |
| Comorbidities,n (%) | 30 (38%) | 10 (31%) | 20 (43%) |
| Charlson Comorbidity Index, n (%) | |||
| 0 | 43 (54%) | 21 (66%) | 22 (47%) |
| 1 | 14 (18%) | 7 (22%) | 7 (15%) |
| 2 | 12 (15%) | 3 (9%) | 9 (20%) |
| 3 | 6 (8%) | 1 (3%) | 5 (11%) |
| 4 | 3 (4%) | 0 (0%) | 3 (6%) |
| 5 | 1 (1%) | 0 (0%) | 1 (2%) |
| Type of comorbidity, n (%) | |||
| None | 49 (62%) | 22 (68%) | 27 (57%) |
| Essential hypertension | 9 (11%) | 2 (6%) | 7 (14%) |
| Coronary heart disease | 5 (6%) | 0 (0%) | 5 (10%) |
| COPD | 5 (6%) | 0 (0%) | 4 (8%) |
| CMV colitis | 2 (3%) | 0 (0%) | 2 (4%) |
| Psoriasis | 2 (3%) | 2 (6%) | 0 (0%) |
| Ankylosing spondylitis | 2 (3%) | 2 (6%) | 0 (0%) |
| Rheumatoid arthritis | 1 (1%) | 1 (3%) | 0 (0%) |
| Multiple sclerosis | 1 (1%) | 0 (0%) | 1 (2%) |
| Undifferentiated connective tissue disease | 1 (1%) | 1 (3%) | 0 (0%) |
| Hypothyroidism | 1 (1%) | 0 (0%) | 1 (2%) |
| Kaposi’s sarcoma | 1 (1%) | 0 (0%) | 1 (2%) |
| COVID-19-related symptoms, n (%) | |||
| None | 2 (3%) | 1 (3%) | 1 (3%) |
| Fever | 71 (90%) | 28 (88%) | 43 (91%) |
| Cough | 52 (66%) | 19 (59%) | 33 (70%) |
| Dysosmia or dysgeusia | 19 (24%) | 10 (31%) | 9 (19%) |
| Arthralgia or myalgia | 18 (23%) | 10 (31%) | 8 (17%) |
| Dyspnoea | 15 (19%) | 8 (25%) | 7 (15%) |
| Diarrhoea | 12 (15%) | 5 (16%) | 7 (15%) |
| Rhino-pharyngitis | 13 (16%) | 8 (26%) | 5 (10%) |
| Dysphonia | 1 (1%) | 1 (1%) | 0 (0%) |
| Conjunctivitis | 1 (1%) | 1 (1%) | 0 (0%) |
CD, Crohn’s disease; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease.